Attached files

file filename
EX-99.3 - PRESENTATION SLIDES - QUESTCOR PHARMACEUTICALS INCd301915dex993.htm
EX-99.1 - PRESS RELEASE - QUESTCOR PHARMACEUTICALS INCd301915dex991.htm
EX-99.2 - TRANSCRIPT OF CONFERENCE CALL - QUESTCOR PHARMACEUTICALS INCd301915dex992.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

February 22, 2012 Date of Report (Date of earliest event reported): February 22, 2012

 

 

QUESTCOR PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

 

 

 

California   001-14758   33-0476164

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

1300 Kellogg Drive, Suite D, Anaheim, California   92807
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (714) 786-4200

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 2.02. Results of Operation and Financial Condition.

On February 22, 2012, Questcor Pharmaceuticals, Inc. (the “Company”) announced via press release certain operating and financial results for the quarter and year ended December 31, 2011. A copy of the Company’s press release is attached hereto as Exhibit 99.1.

Also on February 22, 2012, the Company held a conference call with analysts and investors, the transcript and presentation slides of which are filed as Exhibit 99.2 and Exhibit 99.3, respectively, and both of which are incorporated herein by reference.

In accordance with General Instruction B.2. of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K, including Exhibits 99.1, 99.2 and 99.3, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit No.

  

Description

99.1

   Questcor Pharmaceuticals, Inc. press release dated February 22, 2012.

99.2

   Transcript of conference call held on February 22, 2012.

99.3

   Presentation slides used during conference call held on February 22, 2012.


SIGNATURES

Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: February 24, 2012   QUESTCOR PHARMACEUTICALS, INC.
  By:  

/s/ Michael H. Mulroy

    Michael H. Mulroy
    Senior Vice President, Chief Financial Officer, and General Counsel


EXHIBIT INDEX

 

Exhibit No.

  

Description

99.1    Questcor Pharmaceuticals, Inc. press release dated February 22, 2012.
99.2    Transcript of conference call held on February 22, 2012.
99.3    Presentation slides used during conference call held on February 22, 2012.